The 2015 Agency Issue

Agency business again appears to be up for a healthy cross-section of companies this year

Five things for pharma marketers to know: Thursday, July 2

Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower ...

Sermo expands to Canada in global expansion

The social networking site for doctors also plans to expand to its first Spanish-speaking country next month.

Welcome to MM&M's 2015 Agency Issue!
Here you'll find original profiles of the Top 100 healthcare marketing and advertising firms in North America, plus findings of our annual business barometer survey, a table ranking the 100 agencies by 2014 revenue, an infographic of the agency universe, a Q&A with holding-company level health execs, and the Agency A to Z definitive annual directory.

Latest

Pharmacy groups urge consistent naming of biosimilars

Pharmacy groups urge consistent naming of biosimilars

The health insurance industry's trade association, along with other organizations, sent a letter to the FDA arguing that different names could lead to prescriber confusion and medication errors.

Five things for pharma marketers to know: Wednesday, July 1

Five things for pharma marketers to know: Wednesday, July 1

Purdue withdraws plans to participate in FDA meeting on painkillers; Allscripts takes 10% stake in NantHealth in advance of IPO; union advocates to end pharma support for CME

Five things for pharma marketers to know: Tuesday, June 30

Five things for pharma marketers to know: Tuesday, June 30

Vertex's cystic-fibrosis drug approval likely to come this week; Roche's multiple-sclerosis treatment hits primary and secondary endpoints; Regeneron/Sanofi debut film about high cholesterol

Manufacturers pay $6.5 billion to healthcare providers in 2014

Manufacturers pay $6.5 billion to healthcare providers in 2014

The government released new data showing how much pharma and device companies spent for research and marketing purposes last year.

Havas Health acquires London-based PR shop

Havas Health acquires London-based PR shop

Havas Health adds PR agency Just:: Health Communications in bid to expand its global footprint.

Five things for pharma marketers to know: Monday, June 29

Five things for pharma marketers to know: Monday, June 29

A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again

Five things for pharma marketers to know: Friday, June 26

Five things for pharma marketers to know: Friday, June 26

Supreme Court affirmed the legality of the Affordable Care Act for a second time on Thursday

Myelin acquires agencies in Chicago and Atlanta

Myelin acquires agencies in Chicago and Atlanta

Fourth and fifth members of network add healthcare advertising and PR expertise.

Five things for pharma marketers to know: Wednesday, June 24

Five things for pharma marketers to know: Wednesday, June 24

AbbVie says curative effects hold whether Viekira Pak used with or without ribavirin; House Republicans vote to eliminate IPAB; analyst sets high price target for Alexion.

Treato bolsters social-media insight

The consumer-insights firm said it's debuting a listening feature that will make it harder for pharma to ignore Twitter, Reddit and the other big social platforms.

BMS combo would gain heft in melanoma space, say analysts

BMS combo would gain heft in melanoma space, say analysts

The promise of an Opdivo/Yervoy combination, now awaiting FDA approval, has more to do with payer strategy than efficacy, analysts say.

Five things for pharma marketers to know: Tuesday, June 23

Five things for pharma marketers to know: Tuesday, June 23

Adults dominate the ADHD prescription category; the FDA approved The Medicine Company's anticlotting drug 10 years after issuing a CRL; a survey shows personalized content can build consumer goodwill

Studies show blood thinner antidotes work

Clinical trial results for experimental antidotes to oral anticoagulants Pradaxa and Eliquis indicate they reverse blood thinners in a short time.

Agency Spotlight


Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.